Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | RXRG | P48443 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721165 | 0.85 | SLC2A1 (0.59) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8728948 | 0.85 | SLC2A1 (0.59) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL27997579 | 0.83 | RXRA (0.71) | RXRARXRBRXRGHTR2CSLC6A4 | |
| SCHEMBL3550476 | 0.83 | SLC6A4 (0.56) | RXRARXRBRXRGLMNASLC6A4 | |
| SCHEMBL31751182 | 0.83 | SLC6A4 (0.56) | RXRARXRBRXRGLMNASLC6A4 | |
| SCHEMBL3548452 | 0.82 | RXRA (0.75) | RXRARXRBRXRGMRGPRX4NPC1 | |
| SCHEMBL6208606 | 0.80 | MRGPRX4 (0.50) | RXRARXRBRXRGLMNACYP1A2 | |
| SCHEMBL3954569 | 0.80 | RXRA (0.52) | RXRARXRBRXRGLMNANPC1 | |
| SCHEMBL3960500 | 0.79 | RXRA (0.49) | RXRARXRBRXRGLMNANPC1 | |
| SCHEMBL3026638 | 0.79 | EPHX2 (0.41) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942733-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2005-04-27 | — | — | EP | disclosed |
| EP-0941093-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-0941092-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2004-12-29 | — | — | EP | disclosed |
| EP-0942732-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6613765-B1 | Administering compounds such as 2-(1-(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4 -triazolo)methyl)morpholine; sustained release antidepressants with side effect reduction | MERCK SHARP & DOHME LIMITED | 2003-09-02 | — | — | US | disclosed |
| US-6271230-B1 | ADMINISTERING NEUROKININ RECEPTOR ANTAGONIST | MERCK SHARP & DOHME LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| US-6156749-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
| US-6114315-A | ORAL ADMINISTERING; SIDE EFFECT REDUCTION | MERCK SHARP & DOHME LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| US-6100256-A | ORALLY ADMINISTERING AN ORALLY ACTIVE, LONG ACTING, CENTRAL NERVOUS SYSTEM-PENETRANT NK-1(NEUROKININ-1, SUBSTANCE P) RECEPTOR ANTAGONIST; FOR PATIENT WHO IS NON-RESPONSIVE TO, OR FOR WHOM ANTIPSYCHOTIC AGENTS ARE CONTRAINDICATED | MERCK SHARP & DOHME LTD. (GB) | 2000-08-08 | — | — | US | disclosed |
| US-6096729-A | Use of NK-1 receptor antagonists for treating amnestic disorders | MERCK SHARP & DOHME LTD. (GB) | 2000-08-01 | — | — | US | disclosed |
| US-6090819-A | Use of NK-1 receptor antagonists for treating mania | MERCK SHARP & DOHME, LTD. (GB) | 2000-07-18 | — | — | US | disclosed |
| US-6087348-A | TREATING PHYSIOLOGICAL DISORDERS OR PSYCHOLOGICAL DISORDERS WITH NEUROKININ 1 (SUBSTANCE P) RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ORAL ONCE-A-DAY MEDICAMENT | MERCK SHARP & DOHME LTD. (GB) | 2000-07-11 | — | — | US | disclosed |
| US-5977104-A | Use of NK-1 receptor antagonists for treating bipolar disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| US-5952315-A | TREATING PHYSIOLOGICAL DISORDERS, DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS ANXIETY, DEPRESSION AND PSYCHOSIS WITH AN ANTIDEPRESSANT | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5952330-A | A HETEROCYCLE-ALKYLMORPHOLINES FOR TREATING PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5929054-A | Use of NK-1 receptor antagonists for treating sexual dysfunctions | MERCK SHARP (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5925627-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5919781-A | Use of NK-1 receptor antogonists for treating substance use disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-06 | — | — | US | disclosed |
| WO-1999007374-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |